Binciken Nasara Ya Tabbatar da Tsaro da Inganci na CD19/CD20 Maganin CAR-T don r/r B-NHL

Wani sabon bincike da aka buga a cikin Jiniyana nuna nasarar ci gaban prizloncabtagene autoleucel (prizlon-cel), wani sabon maganin ƙwayoyin CAR-T mai amfani da CD19/CD20, don magance sake dawowa/rage ƙarfin ƙwayoyin B Lymphoma na NonHodgkin (r/r B-NHL). Gwajin, wani bincike mai matakai na 1, wanda aka gudanar a wurare da dama, wanda aka yi a China, ya bayar da bayanai masu kyau kan aminci da ingancin wannan hanyar da aka yi niyya ta hanyoyi biyu.

Binciken wanda ƙungiyar masu bincike daga cibiyoyi, ciki har da Asibitin Farko da ke Jami'ar Zhejiang da Jami'ar Tongji suka jagoranta, ya ƙunshi marasa lafiya 48 da ke fama da cutar r/r B-NHL, waɗanda galibinsu manya ne. Lymphoma na B-Cell (LBCL). A baya majinyata sun yi matsakaicin layi uku na magani. Mahalarta sun sami jiko ɗaya na prizlon-cel bayan maganin chemotherapy na lymphodepleting, tare da allurai tsakanin matakai uku (DL1, DL2, da DL3).

Muhimman Abubuwan da aka gano:

• Bayanin Tsaro: Ba a ga wani abu mai guba da ke iyakance yawan shan magani ba (DLT), kuma maganin ya nuna illolin da za a iya shawo kansu. Ciwon sakin Cytokine (CRS) ya faru a cikin kashi 93.8% na marasa lafiya, galibi a mataki na 1-2, tare da mutum ɗaya kawai a mataki na 3. Ciwon neurotoxicity da ke da alaƙa da ƙwayoyin rigakafi (ICANS) ba kasafai yake faruwa ba kuma mai sauƙi, ba tare da wani sakamako na aji na 3 ko sama da haka ba.
• Inganci: An cimma jimillar ƙimar amsawa (ORR) na kashi 91.5%, tare da cikakken ƙimar amsawa (CR) na kashi 85.1%. Daga cikin marasa lafiya na LBCL, ƙimar ORR da CR sun kasance kashi 90.7% da 86.0%, bi da bi. Abin mamaki, kashi 48.9% na marasa lafiya sun ci gaba da CR a binciken ƙarshe, tare da wasu martanin da suka wuce shekaru uku.
• Sakamakon Rayuwa: Kiyasin Kaplan-Meier ya nuna tsawon shekaru 2 na amsawa (DOR), rayuwa ba tare da ci gaba ba (PFS), da kuma jimillar adadin rayuwa (OS) na 66.0%, 62.6%, da 76.5%, bi da bi. A cikin marasa lafiya na CR, waɗannan adadin sun fi yawa.

Prizlon-cel ya nuna ƙarfin faɗaɗawa da juriya na dogon lokaci, tare da matsakaicin lokacin murmurewa na ƙwayoyin B na kwanaki 185. Tsarin sa mai niyya biyu yana magance tseratar antigen, wata hanyar juriya gama gari a cikin magungunan CAR-T.